Ideally, all future clinical studies targeting EGFR should include pre-/post- tissue EGFR expression, and measurement of intra-tumoral drug concentration in both enhancing and non-enhancing regions of the tumor on the MRI (magnetic resonance imaging). The gene discussed is EGFR; the disease is neoplasm.